TapewireFind a company

person · Reporting owner

PERLMUTTER ROGER M

Disclosed activity across 4 companies

Tapewire entity
11869
SEC CIK
0001184228

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AMGEN INCAMGN · Entity 2832EVP, Research & DevelopmentFebruary 02, 2012February 06, 2012
Eikon Therapeutics, Inc.EIKN · Entity 5380Director · See remarksMarch 02, 2026March 04, 2026
Merck & Co., Inc.MRK · Entity 2807Exe V-P & Pres, MRLMay 01, 2020May 05, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMGEN INC

Report date February 02, 2012 · Filed February 06, 2012

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect261,031 Reported balance After 2012-02-02 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2012-02-02 · Exercise / conversion · Acquired 75,000 · Balance 261,031

Common StockSEC Table I · non-derivativeDirect186,031 Reported balance After 2012-02-02 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2012-02-02 · Sale · Disposed 75,000 · Balance 186,031

F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.61 · Expires 2012-03-15Direct0 Reported balance After 2012-02-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2012-02-02 · Exercise / conversion · Disposed 75,000 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Eikon Therapeutics, Inc.

Report date March 02, 2026 · Filed March 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01Direct268,176 Reported balance After 2026-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-02 · Grant · Acquired 268,176 · Balance 268,176

F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

Merck & Co., Inc.

Report date May 01, 2020 · Filed May 05, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.67 · Expires 2030-04-30Direct151,029 Reported balance After 2020-05-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-05-01 · Grant · Acquired 151,029 · Balance 151,029

F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

Common StockSEC Table I · non-derivativeDirect215,059.579 Reported balance Holding disclosure · report date 2020-05-01 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 215,059.579

F1: Holdings include shares acquired in dividend reinvestment transactions.

Filing footnotes · ownership attribution and instrument terms

F1: Holdings include shares acquired in dividend reinvestment transactions.

F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09Direct0 Reported balance After 2024-04-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17Direct0 Reported balance After 2024-04-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07Direct0 Reported balance After 2024-04-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-04-05 · Disposition to issuer · Disposed 46,238 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 02, 2026 Filed Mar 4, 2026 22:00 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 GrantStock Option (Right to Buy) · Derivative 268,176 $0.00 Strike: $14.88 $0.00
Disclosure

SEC source: 0001193125-26-091779 · ownership.xml · derivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,176

Underlying: Common Stock · 268,176 shares

Expires 2036-03-01

F1 · derivative.exercise_date: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 22:06 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries D Preferred Stock · Derivative 855,512 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-044903 · ownership.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 114,714 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

F2 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

F2 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 22:06 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionSeries A-1 Preferred Stock · Derivative 1,268,891 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-044903 · ownership.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 170,143 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

F1 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

F1 · derivative.exercise_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

F1 · derivative.expiration_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

Read SEC document
February 06, 2026 Filed Feb 10, 2026 22:06 UTC Eikon Therapeutics, Inc. EIKN · Entity 5380 ConversionCommon Stock 284,857 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-044903 · ownership.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 284,857

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:09 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 46,238 Not disclosed Strike: $17.24 Not disclosed
Disclosure

SEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,238 shares

Expires 2031-06-07

F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:09 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 24,222 Not disclosed Strike: $13.35 Not disclosed
Disclosure

SEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,222 shares

Expires 2032-05-17

F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 16:09 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerStock Option (Right to Buy) · Derivative 78,407 Not disclosed Strike: $3.69 Not disclosed
Disclosure

SEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,407 shares

Expires 2033-05-09

F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Read SEC document
May 10, 2023 Filed May 12, 2023 17:49 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 78,407 $0.00 Strike: $3.69 $0.00
Disclosure

SEC source: 0001209191-23-029183 · doc4.xml · derivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,407

Underlying: Common Stock · 78,407 shares

Expires 2033-05-09

F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.

Read SEC document
May 18, 2022 Filed May 20, 2022 18:24 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 24,222 $0.00 Strike: $13.35 $0.00
Disclosure

SEC source: 0001209191-22-031135 · doc4.xml · derivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,222

Underlying: Common Stock · 24,222 shares

Expires 2032-05-17

F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:34 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 GrantStock Option (Right to Buy) · Derivative 46,238 $0.00 Strike: $17.24 $0.00
Disclosure

SEC source: 0001209191-21-039585 · doc4.xml · derivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,238

Underlying: Common Stock · 46,238 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The stock option shall vest one-third on the first anniversary of the date of grant, with the remaining shares vesting quarterly over the next two years, such that the option grant will be fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.

Read SEC document
May 01, 2020 Filed May 5, 2020 20:52 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (Right to Buy) · Derivative 151,029 $0.00 Strike: $77.67 $0.00
Disclosure

SEC source: 0001127602-20-015456 · form4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,029

Underlying: Common Stock · 151,029 shares

Expires 2030-04-30

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 22:39 UTC Merck & Co., Inc. MRK · Entity 2807 GrantCommon Stock 35,049 $76.56 $2,683,351.44
Disclosure

SEC source: 0001127602-20-009162 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,428.496

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
May 03, 2019 Filed May 7, 2019 23:41 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 141,134 $0.00 Strike: $80.00 $0.00
Disclosure

SEC source: 0001104659-19-027586 · a4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,134

Underlying: Common Stock · 141,134 shares

Expires 2029-05-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

Read SEC document
February 25, 2019 Filed Feb 27, 2019 23:55 UTC Merck & Co., Inc. MRK · Entity 2807 GrantCommon Stock 32,937 $80.38 $2,647,476.06
Disclosure

SEC source: 0001225208-19-003897 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,335.921

F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
November 08, 2018 Filed Nov 8, 2018 21:31 UTC Merck & Co., Inc. MRK · Entity 2807 Exercise / conversionStock Option (right to buy) · Derivative 225,443 $0.00 Strike: $44.98 $0.00
Disclosure

SEC source: 0001225208-18-015318 · doc4.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 225,443 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

Read SEC document
November 08, 2018 Filed Nov 8, 2018 21:31 UTC Merck & Co., Inc. MRK · Entity 2807 SaleCommon Stock 225,443 $75.27 $16,967,967.40
Disclosure

SEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,554.968

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.2000 to $75.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
November 08, 2018 Filed Nov 8, 2018 21:31 UTC Merck & Co., Inc. MRK · Entity 2807 Exercise / conversionCommon Stock 225,443 $44.98 $10,140,426.14
Disclosure

SEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 366,997.968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 04, 2018 Filed May 8, 2018 21:32 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 146,383 $0.00 Strike: $57.75 $0.00
Disclosure

SEC source: 0001225208-18-008939 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,383

Underlying: Common Stock · 146,383 shares

Expires 2028-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

Read SEC document
February 27, 2018 Filed Mar 2, 2018 00:32 UTC Merck & Co., Inc. MRK · Entity 2807 GrantCommon Stock 34,931 $54.72 $1,911,424.32
Disclosure

SEC source: 0001225208-18-005011 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,906.628

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
May 05, 2017 Filed May 9, 2017 20:42 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 171,184 $0.00 Strike: $63.97 $0.00
Disclosure

SEC source: 0001225208-17-009428 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,184

Underlying: Common Stock · 171,184 shares

Expires 2027-05-04

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

Read SEC document
February 27, 2017 Filed Mar 1, 2017 21:46 UTC Merck & Co., Inc. MRK · Entity 2807 GrantCommon Stock 32,670 $65.85 $2,151,319.50
Disclosure

SEC source: 0001225208-17-005090 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,601.221

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
May 10, 2016 Filed May 12, 2016 15:40 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 271,647 $0.00 Strike: $54.68 $0.00
Disclosure

SEC source: 0001225208-16-033211 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,647

Underlying: Common Stock · 271,647 shares

Expires 2026-05-09

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

Read SEC document
May 06, 2016 Filed May 9, 2016 20:21 UTC Merck & Co., Inc. MRK · Entity 2807 Exercise / conversionRestricted Stock Unit · Derivative 44,464 $54.09 $2,405,057.76
Disclosure

SEC source: 0001225208-16-032906 · doc4.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,464 shares

Expires 2016-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

Read SEC document
May 06, 2016 Filed May 9, 2016 20:21 UTC Merck & Co., Inc. MRK · Entity 2807 Tax withholdingCommon Stock 26,946 $54.09 $1,457,509.14
Disclosure

SEC source: 0001225208-16-032906 · doc4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,953.392

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

Read SEC document
May 06, 2016 Filed May 9, 2016 20:21 UTC Merck & Co., Inc. MRK · Entity 2807 Exercise / conversionCommon Stock 44,464 $0.00 $0.00
Disclosure

SEC source: 0001225208-16-032906 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,899.392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 22, 2016 Filed Feb 24, 2016 17:38 UTC Merck & Co., Inc. MRK · Entity 2807 GrantCommon Stock 25,227 $50.77 $1,280,774.79
Disclosure

SEC source: 0001225208-16-027766 · doc4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,227

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards.

Read SEC document
May 01, 2015 Filed May 5, 2015 20:46 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 247,678 $0.00 Strike: $59.86 $0.00
Disclosure

SEC source: 0001225208-15-011281 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,678

Underlying: Common Stock · 247,678 shares

Expires 2025-04-30

F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.

Read SEC document
May 09, 2014 Filed May 13, 2014 19:55 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 192,572 $0.00 Strike: $58.22 $0.00
Disclosure

SEC source: 0001225208-14-012824 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,572

Underlying: Common Stock · 192,572 shares

Expires 2024-05-08

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015.

Read SEC document
May 06, 2013 Filed May 8, 2013 23:29 UTC Merck & Co., Inc. MRK · Entity 2807 GrantStock Option (right to buy) · Derivative 225,443 $0.00 Strike: $44.98 $0.00
Disclosure

SEC source: 0001225208-13-011736 · doc4.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,443

Underlying: Common Stock · 225,443 shares

Expires 2023-05-05

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014.

Read SEC document
May 06, 2013 Filed May 8, 2013 23:29 UTC Merck & Co., Inc. MRK · Entity 2807 GrantRestricted Stock Unit · Derivative 44,464 $0.00 $0.00
Disclosure

SEC source: 0001225208-13-011736 · doc4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,464

Underlying: Common Stock · 44,464 shares

Expires 2016-05-06

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

Read SEC document
February 02, 2012 Filed Feb 6, 2012 22:35 UTC AMGEN INC AMGN · Entity 2832 Exercise / conversionNqso (Right to Buy) · Derivative 75,000 $0.00 Strike: $58.61 $0.00
Disclosure

SEC source: 0001127602-12-004244 · form4.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,000 shares

Expires 2012-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 02, 2012 Filed Feb 6, 2012 22:35 UTC AMGEN INC AMGN · Entity 2832 SaleCommon Stock 75,000 $69.83 $5,237,325.00
Disclosure

SEC source: 0001127602-12-004244 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,031

F1 · price: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
February 02, 2012 Filed Feb 6, 2012 22:35 UTC AMGEN INC AMGN · Entity 2832 Exercise / conversionCommon Stock 75,000 $58.61 $4,395,750.00
Disclosure

SEC source: 0001127602-12-004244 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 29, 2011 Filed May 2, 2011 23:18 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 1,357 $57.14 $77,538.98
Disclosure

SEC source: 0001127602-11-014447 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,031

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
April 28, 2011 Filed May 2, 2011 23:18 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 1,357 $56.82 $77,104.74
Disclosure

SEC source: 0001127602-11-014447 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,388

Read SEC document
April 26, 2011 Filed Apr 28, 2011 01:18 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 1,357 $54.69 $74,214.33
Disclosure

SEC source: 0001127602-11-013892 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,745

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
April 25, 2011 Filed Apr 28, 2011 01:18 UTC AMGEN INC AMGN · Entity 2832 GrantNqso (Right to Buy) · Derivative 55,125 $54.69 Strike: $54.69 $3,014,786.25
Disclosure

SEC source: 0001127602-11-013892 · form4.xml · derivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,125

Underlying: Common Stock · 55,125 shares

Expires 2021-04-25

F3 · derivative.exercise_date: These non-qualified stock options are exercisable in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively.

Read SEC document
April 25, 2011 Filed Apr 28, 2011 01:18 UTC AMGEN INC AMGN · Entity 2832 GrantCommon Stock 15,800 $0.00 $0.00
Disclosure

SEC source: 0001127602-11-013892 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,102

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
March 11, 2011 Filed Mar 15, 2011 22:38 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 8,179 $51.84 $423,999.36
Disclosure

SEC source: 0001127602-11-010292 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,302

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
March 02, 2011 Filed Mar 5, 2011 00:33 UTC AMGEN INC AMGN · Entity 2832 GrantCommon Stock 17,520 $0.00 $0.00
Disclosure

SEC source: 0001127602-11-009093 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,481

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
April 29, 2010 Filed Apr 30, 2010 22:57 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 1,401 $58.18 $81,510.18
Disclosure

SEC source: 0001127602-10-012677 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,961

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
April 28, 2010 Filed Apr 30, 2010 22:57 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 1,401 $57.84 $81,033.84
Disclosure

SEC source: 0001127602-10-012677 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,362

Read SEC document
April 26, 2010 Filed Apr 28, 2010 19:38 UTC AMGEN INC AMGN · Entity 2832 GrantNqso (Right to Buy) · Derivative 84,000 $58.43 Strike: $58.43 $4,908,120.00
Disclosure

SEC source: 0001127602-10-012260 · form4.xml · derivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,000

Underlying: Common Stock · 84,000 shares

Expires 2020-04-26

F3 · derivative.exercise_date: These options are exercisable in four equal annual installments of 25% each commencing 04/26/2011.

Read SEC document
April 26, 2010 Filed Apr 28, 2010 19:38 UTC AMGEN INC AMGN · Entity 2832 GrantCommon Stock 12,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-10-012260 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,763

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Company's 2009 Equity Incentive Plan and vest in four equal annual installments of 25% each commencing April 26, 2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/28/2010; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Read SEC document
March 12, 2010 Filed Mar 16, 2010 19:17 UTC AMGEN INC AMGN · Entity 2832 Tax withholdingCommon Stock 5,753 $57.49 $330,739.97
Disclosure

SEC source: 0001127602-10-008777 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,763

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person.

Read SEC document
March 12, 2010 Filed Mar 16, 2010 19:17 UTC AMGEN INC AMGN · Entity 2832 GrantCommon Stock 12,324 $0.00 $0.00
Disclosure

SEC source: 0001127602-10-008777 · form4.xml · nonDerivative · entry 1

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,516

Read SEC document
June 02, 2009 Filed Jun 2, 2009 23:22 UTC AMGEN INC AMGN · Entity 2832 Exercise / conversionNqso (Right to Buy) · Derivative 82,391 $0.00 Strike: $38.36 $0.00
Disclosure

SEC source: 0001127602-09-012973 · form4.xml · derivative · entry 5

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82,391 shares

Expires 2009-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 02, 2009 Filed Jun 2, 2009 23:22 UTC AMGEN INC AMGN · Entity 2832 Exercise / conversionIso (Right to Buy) · Derivative 2,609 $0.00 Strike: $38.36 $0.00
Disclosure

SEC source: 0001127602-09-012973 · form4.xml · derivative · entry 4

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,609 shares

Expires 2009-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 02, 2009 Filed Jun 2, 2009 23:22 UTC AMGEN INC AMGN · Entity 2832 SaleCommon Stock 85,000 $51.07 $4,340,865.00
Disclosure

SEC source: 0001127602-09-012973 · form4.xml · nonDerivative · entry 3

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,192

F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person.

F2 · price: The sale price is an average sale price with a low of $51.00 per share and a high of $51.19 per share. A detailed list of the number of shares sold and the sale price of each share is available upon request by the SEC staff, the issuer or a security holder of the issuer.

Read SEC document
June 02, 2009 Filed Jun 2, 2009 23:22 UTC AMGEN INC AMGN · Entity 2832 Exercise / conversionCommon Stock 82,391 $38.36 $3,160,518.76
Disclosure

SEC source: 0001127602-09-012973 · form4.xml · nonDerivative · entry 2

PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,192

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.